PapersFlow Research Brief
Erythropoietin and Anemia Treatment
Research Guide
What is Erythropoietin and Anemia Treatment?
Erythropoietin and anemia treatment refers to the therapeutic use of erythropoietin and erythropoiesis-stimulating agents to correct anemia in conditions such as chronic kidney disease, end-stage renal disease, heart failure, and chronic diseases by stimulating red blood cell production.
The field encompasses 31,276 papers on erythropoietin derivatives for managing anemia associated with chronic kidney disease, heart failure, stroke, cancer, and iron deficiency. Key studies demonstrate that recombinant human erythropoietin increases hematocrit and reduces transfusion needs in hemodialysis patients with end-stage renal disease. Advances address iron homeostasis disturbances and blunted erythropoietin responses in anemia of chronic disease.
Topic Hierarchy
Research Sub-Topics
Erythropoiesis-Stimulating Agents in CKD
This sub-topic covers the use of ESAs like epoetin alfa and darbepoetin for anemia correction in chronic kidney disease patients. Research examines dosing, hemoglobin targets, and cardiovascular risks.
Erythropoietin Neuroprotection
Investigates EPO's protective effects in stroke, hypoxia, and neurodegeneration via anti-apoptotic and neurotrophic mechanisms. Preclinical and clinical trials explore non-hematopoietic applications.
Anemia Management in Heart Failure
Studies the role of erythropoietin, iron therapy, and ESAs in improving outcomes for anemic heart failure patients. Research addresses interactions with hypoxia-inducible factors and cardiovascular events.
Iron Deficiency in Erythropoietin Therapy
Explores iron supplementation strategies like ferric carboxymaltose alongside EPO to optimize anemia correction. Focuses on chronic disease anemia, CKD, and heart failure contexts.
Erythropoietin in Cancer-Related Anemia
Examines ESAs for chemotherapy-induced anemia, balancing benefits against tumor progression risks. Research includes guidelines, outcomes, and hypoxia-inducible factor modulation.
Why It Matters
Erythropoietin therapies have transformed anemia management in chronic kidney disease, with Eschbach et al. (1987) showing that recombinant human erythropoietin administered intravenously three times weekly to 25 hemodialysis patients raised hematocrit from baseline levels and eliminated transfusion requirements. In heart failure, Anker et al. (2009) found intravenous ferric carboxymaltose improved symptoms, functional capacity, and quality of life in patients with iron deficiency, regardless of anemia presence (ClinicalTrials.gov NCT00520780). Singh et al. (2006) reported targeting hemoglobin to 13.5 g/dL with epoetin alfa increased risks without quality-of-life gains, guiding safer hemoglobin targets below 13.5 g/dL in non-dialysis CKD patients. These applications reduce transfusion dependence in critically ill patients, as Vincent (2002) observed anemia prevalence and transfusion associations with organ dysfunction.
Reading Guide
Where to Start
"Correction of the Anemia of End-Stage Renal Disease with Recombinant Human Erythropoietin" by Eschbach et al. (1987), as it provides foundational evidence of erythropoietin's efficacy in raising hematocrit and eliminating transfusions in hemodialysis patients.
Key Papers Explained
Eschbach et al. (1987) "Correction of the Anemia of End-Stage Renal Disease with Recombinant Human Erythropoietin" established recombinant erythropoietin's role in hemodialysis anemia. Singh et al. (2006) "Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease" and Drüeke et al. (2006) "Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia" built on this by testing higher hemoglobin targets, revealing increased risks without benefits. Pfeffer et al. (2009) "A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease" extended findings to diabetic non-dialysis patients, showing no outcome improvements.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Recent emphasis remains on balancing erythropoiesis-stimulating agents with iron therapies to avoid cardiovascular risks, as seen in trials like Anker et al. (2009) on ferric carboxymaltose in heart failure. No new preprints or news in the last 12 months indicate steady focus on established protocols from top-cited NEJM studies.
Papers at a Glance
Frequently Asked Questions
What causes anemia of chronic disease?
Anemia of chronic disease arises from disturbances in iron homeostasis, impaired erythroid progenitor cell proliferation, and blunted erythropoietin response. Weiß and Goodnough (2005) outline these mechanisms in their review. New therapeutic strategies target these pathways to improve outcomes.
How does recombinant human erythropoietin treat anemia in end-stage renal disease?
Recombinant human erythropoietin given intravenously three times weekly after dialysis increases hematocrit, improves ferrokinetics, and reduces transfusion requirements in anemic hemodialysis patients. Eschbach et al. (1987) administered it to 25 patients with end-stage renal disease. Hematocrit rose steadily, eliminating the need for transfusions.
What hemoglobin target is recommended in chronic kidney disease anemia?
Targeting hemoglobin to 13.5 g/dL with epoetin alfa in chronic kidney disease patients increases cardiovascular risk without quality-of-life benefits compared to 11.3 g/dL. Singh et al. (2006) demonstrated this in their trial (ClinicalTrials.gov NCT00211120). Lower targets are safer for non-dialysis patients.
Does complete anemia correction benefit chronic kidney disease patients?
Early complete correction of anemia in chronic kidney disease does not reduce cardiovascular event risks. Drüeke et al. (2006) found normalization of hemoglobin levels offered no such benefit (ClinicalTrials.gov NCT00321919). Partial correction suffices to manage symptoms.
What is the role of darbepoetin alfa in diabetic chronic kidney disease?
Darbepoetin alfa in type 2 diabetes patients with chronic kidney disease and moderate anemia does not reduce risks of death, cardiovascular events, or renal events. Pfeffer et al. (2009) reported increased risks with its use in non-dialysis patients. It fails to improve primary composite outcomes.
How does iron therapy aid heart failure patients with anemia?
Intravenous ferric carboxymaltose treats iron deficiency in chronic heart failure patients, improving symptoms, functional capacity, and quality of life, with or without anemia. Anker et al. (2009) confirmed an acceptable side-effect profile (ClinicalTrials.gov NCT00520780). It addresses iron deficiency directly.
Open Research Questions
- ? What optimal hemoglobin targets minimize cardiovascular risks in CKD patients on erythropoiesis-stimulating agents?
- ? How do iron homeostasis disturbances interact with erythropoietin responses in anemia of chronic disease?
- ? Does partial versus full anemia correction differentially affect outcomes in non-dialysis CKD populations?
- ? What mechanisms underlie increased cardiovascular events with higher hemoglobin normalization in CKD?
- ? How effective are erythropoiesis-stimulating agents in reducing transfusions without elevating thrombosis risks in critically ill patients?
Recent Trends
The field includes 31,276 works with no reported 5-year growth rate; foundational trials like Singh et al. and Drüeke et al. (2006) continue to shape hemoglobin target practices, emphasizing levels below 13.5 g/dL. No recent preprints or news coverage in the last 12 months signals stable reliance on established erythropoietin and iron therapies from 1987-2009 NEJM papers.
2006Research Erythropoietin and Anemia Treatment with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Erythropoietin and Anemia Treatment with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers